PriMera Scientific Medicine and Public Health (ISSN: 2833-5627)

Review Article

Volume 4 Issue 5

Decoding Nanomedicine in Tackling Cardiovascular Diseases; Reaching the Unreached

Deepa Rajendiran*, Alexander Kiruthiga and Subbulakshmi Packirisamy

April 22, 2024

DOI : 10.56831/PSMPH-04-139

View PDF

Abstract

Cardiovascular diseases (CVDs) pose a serious global threat as they are a significant cause of morbidity and mortality claiming a large number of lives. Increased incidences of cardiovascular events are often associated with an increased uptake of unbalanced dietary high-saturated lipids, salt and sugar. A sedentary lifestyle as well as obesity contribute to other potential factors leading to cardiovascular diseases. Demerits of limited applications in the diagnosis and treatment strategy of CVDs have led to the further exploration of nanoparticles in medicine. The field of Nanomedicine based on employing nanoparticles has revolutionized the diagnostic and therapeutic landscape by playing an important role in identifying their targets, signaling process and efficient drug delivery. These nanotechnology-driven methods can serve as efficient biomarkers in the early detection of CVDs thereby helping in their therapeutic and future prevention of cardiovascular events.

Keywords: Nanomedicine; Cardiovascular Diseases; Drug delivery; Biomarker

References

  1. Saba L., et al. “International Union of Angiology (IUA) consensus paper on imaging strategies in atherosclerotic carotid artery imaging: From basic strategies to advanced approaches”. Atherosclerosis 354 (2022): 23-40.
  2. https://www.who.int/india/health-topics/cardiovascular-diseases
  3. Walden R and Tomlinson B. “Cardiovascular Disease”. In I. F. F. Benzie (Eds.) et. al., Herbal Medicine: Biomolecular and Clinical Aspects. (2nd ed.). CRC Press/Taylor & Francis.
  4. Laflamme MA and Murry CE. “Heart regeneration”. Nature 473.7347 (2011): 326-335.
  5. Prajnamitra RP., et al. “Nanotechnology Approaches in Tackling Cardiovascular Diseases”. Molecules 24.10 (2019): 2017.
  6. Jebari-Benslaiman S., et al. “Pathophysiology of Atherosclerosis”. Int J Mol Sci 23.6 (2022): 3346.
  7. Jung E., et al. “Serum Cholesterol Levels and Risk of Cardiovascular Death: A Systematic Review and a Dose-Response Meta-Analysis of Prospective Cohort Studies”. Int J Environ Res Public Health 19.14 (2022): 8272.
  8. Kjeldsen SE. “Hypertension and cardiovascular risk: General aspects”. Pharmacol Res 129 (2018): 95-99.
  9. Wang Z, Yang T and Fu H. “Prevalence of diabetes and hypertension and their interaction effects on cardio-cerebrovascular diseases: a cross-sectional study”. BMC Public Health 21.1 (2021): 1224.
  10. Ruiz-Esparza GU., et al. “The physiology of cardiovascular disease and innovative liposomal platforms for therapy”. Int J Nanomedicine 8 (2013): 629-640.
  11. Chandarana M, Curtis A and Hoskins C. “The use of nanotechnology in cardiovascular disease”. Appl Nanosci 8 (2018): 1607-1619.
  12. Banach M., et al. “Statin intolerance - an attempt at a unified definition”. Position paper from an International Lipid Expert Panel. Arch Med Sci 11.1 (2015): 1-23.
  13. Mackman N., et al. “Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients”. Arterioscler Thromb Vasc Biol38.4 (2018): 726-732.
  14. Geisler T., et al. “Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation”. Eur Heart J 27.20 (2006): 2420-2425.
  15. Abid Haleem., et al. “Applications of nanotechnology in medical field: a brief review”. Global Health Journal (2023).
  16. Tinkle S., et al. “Nanomedicines: addressing the scientific and regulatory gap”. Ann. N. Y. Acad. Sci 1313 (2014): 35-56.
  17. Murthy SK. “Nanoparticles in modern medicine: state of the art and future challenges”. Int J Nanomedicine 2.2 (2007): 129-41.
  18. Jiang W., et al. “Nanomaterials for treating cardiovascular diseases: A review”. Bioact Mater 2.4 (2017): 185-198.
  19. Gupta R and Xie H. “Nanoparticles in Daily Life: Applications, Toxicity and Regulations”. Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer 37.3 (2018): 209-230.
  20. Pala R., et al. “Nanoparticle-Mediated Drug Delivery for the Treatment of Cardiovascular Diseases”. Int J Nanomedicine 15 (2020): 3741-3769.
  21. Mereuta L., et al. “Sequence-specific detection of single-stranded DNA with a gold nanoparticle-protein nanopore approach”. Sci Rep 10 (2020): 16141.
  22. Thupakula S., et al. “Emerging biomarkers for the detection of cardiovascular diseases”. The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology 74.1 (2022): 77.
  23. Hu Q., et al. “Nanotechnology for cardiovascular diseases”. Innovation (Cambridge (Mass.) 3.2 (2022): 100214.
  24. Hesari M., et al. “Current Advances in the Use of Nanophytomedicine Therapies for Human Cardiovascular Diseases”. International journal of nanomedicine 16 (2021): 3293-3315.
  25. Patra JK and Das FL. “Nano based drug delivery systems: recent developments and future prospects”. J Nanobiotechnology 16 (2018).
  26. Siddiqui A., et al. “Role of natural products in drug discovery process”. Int J Drug Dev Res 6.2 (2014): 172-204.
  27. Mushtaq S., et al. “Natural products as reservoirs of novel therapeutic agents”. EXCLI J 17 (2018): 420-451.
  28. Obidah Abert H., et al. “Effect of Green Synthesized Iron Oxide Nanoparticles Using Spinach Extract on Triton X-100-Induced Atherosclerosis in Rats”. Biochemistry Research International (2022).
  29. Liu Y., et al. “Protective properties of nanoparticles green-synthesized by plant on myocardial ischemia”. Inorganic Chemistry Communications 154 (2023): 110902.
  30. Atale N., et al. “Synthesis and characterization of Sygyzium cumini nanoparticles for its protective potential in high glucose-induced cardiac stress: a green approach”. Applied biochemistry and biotechnology 181 (2017): 1140-1154.
  31. Alshehri MA. “Cardioprotective properties of Artemisia herba alba nanoparticles against heart attack in rats: A study of the antioxidant and hypolipidemic activities”. Saudi Journal of Biological Sciences 29.4 (2022): 2336-2347.
  32. Xu N., et al. “Cardioprotective effects of plant-based silver nanoparticles: Describing a modern drug”. Inorganic Chemistry Communications 158 (2023): 11152
  33. Sudjarwo SA., et al. “Cardioprotective activity of chitosan-pinus merkusii extract nanoparticles against lead acetate induced cardiac cell damage in rat”. Rasayan Journal of Chemistry [Internet] 12.1 (2019): 184-91.
  34. Jing C., et al. “Biosynthesis of copper oxide nanoparticles and their potential synergistic effect on alloxan induced oxidative stress conditions during cardiac injury in Sprague-Dawley rats”. Journal of Photochemistry and Photobiology. B, Biology 198 (2019): 111557.
  35. Baharara J., et al. “Green synthesis of silver nanoparticles using Achillea biebersteinii flower extract and its anti-angiogenic properties in the rat aortic ring model”. Molecules 19.4 (2014): 4624-4634.
  36. Tu S., et al. “Copper nanoparticles green-formulated by a medicinal plant: Preparation, characterization and investigation of its cardioprotective effects”. Inorganic Chemistry Communications 155 (2023): 111104.
  37. Lalfakzuala R and Siama Z. “Green Synthesis of Silver Nanoparticles Using Spilanthes acmella Leaf Extract and its Antioxidant-Mediated Ameliorative Activity against Doxorubicin-Induced Toxicity in Dalton's Lymphoma Ascites (DLA)-Bearing Mice”. ACS omega 7.48 (2022): 44346-44359.